Cyclin E, a Powerful Predictor of Survival in Breast Cancer-A Prospective Study
Abstract
Aberrations in expression of cyclin E, a positive cell cycle regulator at the G1 to S transition, may affect the biological behavior of breast cancer. In a retrospective analysis of tumor specimens from 395 breast cancer patients, we found that overexpression of the full-length cyclin E protein and its LMW isoforms was a very strong predictor of breast cancer death regardless of whether patients had lymph node-negative disease or lymph node-positive disease (p <0.0001). Our hypothesis is that dysregulation of cyclin E is a powerful prognostic indicator of outcome in early stage breast cancer. Specifically we will: 1: use cyclin E antibody as a prognostic marker for stage I and II breast cancer in a PROSPECTIVE study, 2: examine the cyclin E associated activity and its immune-complex formation with key cell cycle regulators in freshly resected tumor samples, and 3: develop an immunohistochemical (I HO) assay for specifically detecting the LMW forms of cyclin E in Breast Cancer. We will correlate the cyclin E alterations in samples with the expression of key cell cycle regulators and clinical biomarkers. If we prospectively confirm cyclin E overexpression correlates with poor outcome, clinicians can more appropriately tailor aggressive systemic treatment to those at greatest risk for systemic metastases
Document Details
- Document Type
- Technical Report
- Publication Date
- Jun 01, 2004
- Accession Number
- ADA443979
Entities
People
- Khandan Keyomarsi
Organizations
- The University of Texas MD Anderson Cancer Center